



# The Obesity ETF

## Taking On The Global Obesity Epidemic

The numbers are startling. Over the last 40 years, the population of obese people has risen by more than 600%, with more than 640 million individuals worldwide now classified as obese.<sup>1</sup> This alarming trend has rallied the medical community, governments worldwide and the substantial commercial marketplace to confront and overcome the challenges and costs of obesity.



**640+ MILLION**  
OBESE PEOPLE WORLDWIDE  
OVER 600% RISE IN THE LAST  
40 YEARS<sup>1</sup>

### SLIM - The Obesity ETF

This exchange traded fund provides the opportunity to invest in companies globally that could benefit as they fight the global obesity epidemic, including: companies that provide treatment and care for obesity, including biotechnology, healthcare, obesity and obesity related disease, and companies focused on weight loss programs and supplements.


## Why Invest in the Battle Against Obesity

**A Chronic and Increasing Condition:** Worldwide, more than 10% of men and some 14% of women are classified as obese; those numbers are predicted to climb to 18% of men and 21% of women by 2025. In the U.S., 75% of men and 67% of women ages 25 and older are either overweight or obese.<sup>1</sup>

**Rising Costs:** As obesity and overweight levels rise, so have the enormous direct and indirect medical expenditures for treatment and prevention – creating increased pressure to tackle the issue. Globally, the obesity epidemic costs \$2 trillion a year in health care costs and related lost productivity.<sup>2</sup>

### Paying the Price

Annual cost of direct and indirect medical expenditures for treatment and prevention of various epidemics




Source: Mckinsey Global Institute. As of 4/2015.



LOST WORKER PRODUCTIVITY,  
DISABILITY & EARLY DEATH COSTS  
**\$305 BILLION**  
ANNUALLY<sup>2</sup>

**Sectors beyond Health Care Attacking Obesity:** The sectors taking on the battle against obesity go beyond the health care arena. The global health and wellness market has been growing at 7.2%, with sales expected to reach \$1 trillion by 2017. The weight loss market has exhibited continued strength, in spite of a shift toward medical treatment, with the U.S. market valued at \$64 billion in 2014. The low-calorie food market, pegged at \$7.4 billion in 2013, is predicted to grow to \$10.4 billion by 2019.<sup>3</sup>

### Growth of Health and Wellness Industry in the U.S.\* 2007–2017



2017 was Estimated

Source: Euromonitor International. As of 11/2012.

SLIM



### INVEST IN THE BATTLE AGAINST OBESITY

As the world takes on the global obesity epidemic, opportunities are emerging for a broad set of companies across sectors to make a significant contribution to this challenge. Investors can participate in the potential benefits these companies may realize as they join the global battle against obesity through The Obesity ETF.



JANUS®

To learn more contact your Janus Representative at 877-33JANUS (52687).

\* **Food Intolerance:** Products avoid the use of certain ingredients that could cause food allergies and sensitivities including but not limited to: wheat-free, gluten-free, grain-free and lactose-free to name a few. **Better For You (BFY):** Comprises food and beverages reduced in sugar, fat, salt and/or carbohydrates. **Fortified/Functional (FF):** Includes food with added ingredients such as protein, probiotics and vitamins. **Naturally Healthy (NH):** Includes products that are perceived healthier than highly refined foods including but not limited to: oatmeal, spring water, 100% juice and nut snacks.

<sup>1</sup> Sources: World Health Organization, Washington University School of Medicine, NCD Risk Factor Collaboration. As of 4/2016.

<sup>2</sup> Sources: National Center for Weight & Wellness at George Washington University and the McKinsey Global Institute. As of 4/2015.

<sup>3</sup> Sources: Euromonitor International, Marketdata Enterprises, Transparency Market Research. As of 11/2012.

**OBJECTIVE:** The Obesity ETF (SLIM) seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including, biotechnology, healthcare, obesity and obesity related disease, and companies focused on weight loss programs and supplements.

No investment strategy can ensure a profit or eliminate the risk of loss.

There is no assurance the stated objective(s) will be met.

The ETF is new and has less than one year of operating history.

SLIM focuses its investments in companies that service the obese, many of which are in the health care sector. Because of this, companies in the Fund may share common characteristics and may be more sensitive to factors such as government regulation and cost containment measures, rapid changes in technology, and product cycles. In addition, to the extent the Fund invests a substantial portion of its assets in an industry or group of industries, market or economic factors impacting that industry or group of industries could have a significant effect on the value of the Fund's investments.

Foreign securities are subject to additional risks including currency fluctuations, political and economic uncertainty, increased volatility, lower liquidity and differing financial and information reporting standards, all of which are magnified in emerging markets.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Market returns are based upon the midpoint of the bid/ask spread at 4:00 p.m. Eastern time (when NAV is normally determined for most ETFs), and do not represent the returns you would receive if you traded shares at other times. Ordinary brokerage commissions apply and will reduce returns.

**Please consider the charges, risks, expenses, and investment objectives carefully before investing. For a prospectus containing this and other information, please call 877.33JANUS (52687) or download the file from [janus.com/ETFs](http://janus.com/ETFs). Read it carefully before you invest or send money.**

Janus Capital Management LLC is the investment adviser and ALPS Distributors, Inc. is the distributor. ALPS is not affiliated with Janus.

Janus is a registered trademark of Janus International Holding LLC. © Janus International Holding LLC.

JNS205